Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas Authors retain all rights in any data supplements ...
Real-world data analysis of clinical characteristics and survival outcomes in Russian patients with NSCLC harboring EGFR mutations. A real-world study on first-line (1L) treatment for 46 advanced lung ...
A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These ...
Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer. The approval by the Food and Drug ...
In non-small-cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangement treated with crizotinib, progression-free survival (PFS) varies according to the ALK fusion variant.
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results